PHARC Syndrome, a Rare Genetic Disorder—Case Report Article Swipe

MAKE IMPACT

Paulo Bastos , Marcelo Mendonça , Tânia Lampreia , Marta Magriço , Jorge Oliveira , Raquel Barbosa · YOU? · · 2021 · Open Access · · DOI: https://doi.org/10.1002/mdc3.13266

Polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract (PHARC) is a rare autosomal neurodegenerative disease resulting from mutations on the α/β-hydrolase domain-containing 12 (ABHD12) serine hydrolase encoding gene.1 For the first time reported in 2009 and 48 m/s, Table S1). The phenotype presented (ataxia with RP, demyelinating neuropathy and hearing loss) suggested RD, but the levels of phytanic acid were normal. A lumbar puncture was unremarkable (including for lactate and pyruvate levels). Blood panels were all within normal ranges (including vitamin A and E, copper studies, α-fetoprotein and autoimmune profiling). A formal neuropsychologic evaluation revealed reduced intelligence and an executive deficit. Usher Syndrome had been previously ruled out. Due to the presence of a demyelinating neuropathy with electrophysiological features suggesting a genetic etiology (i.e. CMT-like phenotype), genetic studies for PMP22 gene duplication were requested but the duplication was absent. Muscular biopsy and mitochondrial DNA sequencing ruled out mitochondrial diseases. Screening for germline variations on the ABHD12 gene and validation by sanger sequencing revealed a nonsense homozygous variant [NM 015600.4: c.1054C > T, p.(Arg352*] leading to the substitution of the arginine 352 for a stop codon (Fig. S1). This variant leads to the truncation of an essential protein, has been previously identified in a patient from the USA and reported as pathogenic. We herein present the first case of a Portuguese PHARC patient, highlighting how despite the presence of typical symptoms earlier diagnosis was precluded due to its rarity. Mitochondrial diseases are often assumed in the presence of cataracts, RP and hearing loss, but the presence of polyneuropathy with demyelinating features should be a red flag for this diagnosis. In turn, in a case of ataxia with RP and a demyelinating polyneuropathy, RD should be considered. However, the absence of the systemic findings classically observed in RD should raise awareness for alternative diagnoses. In a Norwegian study, the authors have shown that the disease incidence was ~1/36,000, a frequency comparable to or even higher than that observed for Friedreich Ataxia.1 A variable phenotype presentation with partial symptoms overlap leads to such misdiagnosis when awareness for the condition is not present. Compound heterozygosity and dosage effects in PHARC have been described,3, 5 and even though no clear genotype–phenotype relationship has been established the same can be envisioned (e.g. expression of aberrant proteins, dominant-negatives, gain-of-function effects and compensation phenomena), contributing to the wide range of presentations. In our case, the presenting neurologic complain was tremor, which is present in some but not most PHARC cases reported to date. Both the observed triad of symptoms (RP, hearing loss and demyelinating polyneuropathy) and ataxia with short stature have been previously noted in other patients. In the other patient sharing the same variant herein reported, pyramidal signs had been noted, but this were absent in our patient. Furthermore, the presence of ptosis (no reported cases) and cognitive impairment with learning difficulties (one case to date) herein reported extend the phenotypic spectrum.1 Altogether, the differential diagnosis of Refsum-like disease (Fig. S2) should be expanded to promptly encompass PHARC syndrome. Our understanding of the underlying pathophysiological mechanisms in PHARC is expanding and its accurate diagnosis becomes critical in order to drive further research on the therapeutic approaches that start to be envisioned. (1) Research Project: A. Conception, B. Organization, C. Execution; (2) Statistical Analysis: A. Design, B. Execution, C. Review and Critique; (3) Manuscript Preparation: A. Writing of the First Draft, B. Review and Critique. P.A.D.B.: 1A, AB, 1C, 3A, 3B M.M.: 1A, 1B, 3B T.L.: 3B M.M.: 3B J.O.: 3B R.B.: 1A, AB, 1C, 3A, 3B Written and verbal informed consents were obtained from the patient. The authors confirm that the approval of the institutional review board was not required for this work We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this work is consistent with those guidelines. The authors declare that there are no conflicts of interest relevant to this work. The authors declare that there are no funding sources or conflicts of interest relevant to this work. The authors declare that there are no additional disclosures to report. Figure S1 Mutation validation chromatogram by Sanger Sequencing revealing a nonsense homozygotic mutation [c.1054C > T, p.(Arg352*] responsible for the substitution of a Arginine 352 for a stop codon. Figure S2 The combination of Ataxia and RP and demyelinating PNP can fit in a restricted number of diagnosis that does not include mitochondrial diseases. PHARC should be thought when facing a Refsum-like phenotype. ARSACS—Autosomal recessive spastic ataxia of Charlevoix-Saguenay; CMT4—Charcot Marie Tooth type 4; PHARC - Polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract; CDG1A—Congenital disorder of glycosilation type 1A; ACPHD—Ataxia combined cerebellar and peripheral with hearing loss and DM; AMACRD—Alpha-methylacyl-CoA racemase; NARP—Neuropathy, ataxia, retinitis pigmentosa; SCA 7—Spinocerebellar ataxia type 7; SCA34—Spinocerebellar ataxia type 34; NLC10—neuronal ceroid lipofuscinosis type 10 Table S1 Supplementary details on nerve conduction studies revealing demyelination sensorimotor polyneuropathy on both upper and lower limbs with no conduction blocks and conduction velocities of 17–22 m/s (normal >48 m/s). Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

Type

article

Language

en

Landing Page

https://doi.org/10.1002/mdc3.13266

PDF

https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/mdc3.13266

OA Status

bronze

Cited By

11

References

5

Related Works

10

OpenAlex ID

https://openalex.org/W3166420510

Raw OpenAlex JSON

OpenAlex ID

https://openalex.org/W3166420510

Canonical identifier for this work in OpenAlex

DOI

https://doi.org/10.1002/mdc3.13266

Digital Object Identifier

Title

PHARC Syndrome, a Rare Genetic Disorder—Case Report

Work title

Type

article

OpenAlex work type

Language

en

Primary language

Publication year

2021

Year of publication

Publication date

2021-06-17

Full publication date if available

Authors

Paulo Bastos, Marcelo Mendonça, Tânia Lampreia, Marta Magriço, Jorge Oliveira, Raquel Barbosa

List of authors in order

Landing page

https://doi.org/10.1002/mdc3.13266

Publisher landing page

PDF URL

https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/mdc3.13266

Direct link to full text PDF

Open access

Yes

Whether a free full text is available

OA status

bronze

Open access status per OpenAlex

OA URL

https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/mdc3.13266

Direct OA link when available

Concepts

Medicine, Pes cavus, Retinitis pigmentosa, Ataxic Gait, Ataxia, Hearing loss, Nystagmus, Pediatrics, Surgery, Audiology, Ophthalmology, Retinal, Complication, Psychiatry

Top concepts (fields/topics) attached by OpenAlex

Cited by

11

Total citation count in OpenAlex

Citations by year (recent)

2025: 3, 2024: 7, 2023: 1

Per-year citation counts (last 5 years)

References (count)

5

Number of works referenced by this work

Related works (count)

10

Other works algorithmically related by OpenAlex

Full payload